Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin

Detalhes bibliográficos
Autor(a) principal: Gomes,Juliana P. M.
Data de Publicação: 2011
Outros Autores: Cardoso,Cássia R. P., Varanda,Eliana A., Molina,José-Manuel, Fernandez,Mariana F., Olea,Nicolás, arlos,Iracilda Z., Vilegas,Wagner
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Brasileira de Farmacognosia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000600005
Resumo: Cancer constitutes the second main mortality cause in the world, after cardiovascular diseases. In spite of the progresses in the chemotherapeutics treatments, many patients fail chemotherapy, mainly because of side effects or multi-drugs resistance, proving the need and importance of the research for new molecules with anticancer activity, more effective and with smaller adverse effects. Various compounds derived from plant secondary metabolites are commonly used in the chemotherapy against cancer and the natural products play an important role in the research for new molecules. Among several molecules of natural origin evaluated by MTT assay in murine tumor cell lines [breast (LM3) and lung (LP07)] the quinona-methide triterpenes tingenone and pristimerin showed marked cytotoxic activity presenting IC50 around 2 and 5 µM respectively. The structure-activity relationship suggests that rings A and B containing an α, ß-unsaturated carbonyl group are essential for the observed cytotoxic activity. The interaction between these positions and acetylcisteyne residues suggests a probable mechanism of action. The in vitro mutagenic activity was also evaluated by the Salmonella microsome assay (Ames test) for pristimerin and tingenone with and without metabolic activation (S9) in the strains TA98, TA97a, TA100 and TA102, none of which showed mutagenic potential in any strains. Estrogenic and anti-estrogenic activities were also studied by the e-screen assay in MCF-7 cells with negative results. The present data point to the importance of pristimerin and tingenone as representative of an emerging class of potential anticancer chemicals.
id SBFGNOSIA-1_39e6630aad8dbecea5be7c082b97fed4
oai_identifier_str oai:scielo:S0102-695X2011000600005
network_acronym_str SBFGNOSIA-1
network_name_str Revista Brasileira de Farmacognosia (Online)
repository_id_str
spelling Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin(anti)estrogenic activitycytotoxic activitymutagenic activityplumericinpristimerintingenoneCancer constitutes the second main mortality cause in the world, after cardiovascular diseases. In spite of the progresses in the chemotherapeutics treatments, many patients fail chemotherapy, mainly because of side effects or multi-drugs resistance, proving the need and importance of the research for new molecules with anticancer activity, more effective and with smaller adverse effects. Various compounds derived from plant secondary metabolites are commonly used in the chemotherapy against cancer and the natural products play an important role in the research for new molecules. Among several molecules of natural origin evaluated by MTT assay in murine tumor cell lines [breast (LM3) and lung (LP07)] the quinona-methide triterpenes tingenone and pristimerin showed marked cytotoxic activity presenting IC50 around 2 and 5 µM respectively. The structure-activity relationship suggests that rings A and B containing an α, ß-unsaturated carbonyl group are essential for the observed cytotoxic activity. The interaction between these positions and acetylcisteyne residues suggests a probable mechanism of action. The in vitro mutagenic activity was also evaluated by the Salmonella microsome assay (Ames test) for pristimerin and tingenone with and without metabolic activation (S9) in the strains TA98, TA97a, TA100 and TA102, none of which showed mutagenic potential in any strains. Estrogenic and anti-estrogenic activities were also studied by the e-screen assay in MCF-7 cells with negative results. The present data point to the importance of pristimerin and tingenone as representative of an emerging class of potential anticancer chemicals.Sociedade Brasileira de Farmacognosia2011-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000600005Revista Brasileira de Farmacognosia v.21 n.6 2011reponame:Revista Brasileira de Farmacognosia (Online)instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)instacron:SBFGNOSIA10.1590/S0102-695X2011005000153info:eu-repo/semantics/openAccessGomes,Juliana P. M.Cardoso,Cássia R. P.Varanda,Eliana A.Molina,José-ManuelFernandez,Mariana F.Olea,Nicolásarlos,Iracilda Z.Vilegas,Wagnereng2011-10-18T00:00:00Zoai:scielo:S0102-695X2011000600005Revistahttp://www.sbfgnosia.org.br/revista/https://old.scielo.br/oai/scielo-oai.phprbgnosia@ltf.ufpb.br1981-528X0102-695Xopendoar:2011-10-18T00:00Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)false
dc.title.none.fl_str_mv Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
title Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
spellingShingle Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
Gomes,Juliana P. M.
(anti)estrogenic activity
cytotoxic activity
mutagenic activity
plumericin
pristimerin
tingenone
title_short Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
title_full Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
title_fullStr Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
title_full_unstemmed Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
title_sort Antitumoral, mutagenic and (anti)estrogenic activities of tingenone and pristimerin
author Gomes,Juliana P. M.
author_facet Gomes,Juliana P. M.
Cardoso,Cássia R. P.
Varanda,Eliana A.
Molina,José-Manuel
Fernandez,Mariana F.
Olea,Nicolás
arlos,Iracilda Z.
Vilegas,Wagner
author_role author
author2 Cardoso,Cássia R. P.
Varanda,Eliana A.
Molina,José-Manuel
Fernandez,Mariana F.
Olea,Nicolás
arlos,Iracilda Z.
Vilegas,Wagner
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gomes,Juliana P. M.
Cardoso,Cássia R. P.
Varanda,Eliana A.
Molina,José-Manuel
Fernandez,Mariana F.
Olea,Nicolás
arlos,Iracilda Z.
Vilegas,Wagner
dc.subject.por.fl_str_mv (anti)estrogenic activity
cytotoxic activity
mutagenic activity
plumericin
pristimerin
tingenone
topic (anti)estrogenic activity
cytotoxic activity
mutagenic activity
plumericin
pristimerin
tingenone
description Cancer constitutes the second main mortality cause in the world, after cardiovascular diseases. In spite of the progresses in the chemotherapeutics treatments, many patients fail chemotherapy, mainly because of side effects or multi-drugs resistance, proving the need and importance of the research for new molecules with anticancer activity, more effective and with smaller adverse effects. Various compounds derived from plant secondary metabolites are commonly used in the chemotherapy against cancer and the natural products play an important role in the research for new molecules. Among several molecules of natural origin evaluated by MTT assay in murine tumor cell lines [breast (LM3) and lung (LP07)] the quinona-methide triterpenes tingenone and pristimerin showed marked cytotoxic activity presenting IC50 around 2 and 5 µM respectively. The structure-activity relationship suggests that rings A and B containing an α, ß-unsaturated carbonyl group are essential for the observed cytotoxic activity. The interaction between these positions and acetylcisteyne residues suggests a probable mechanism of action. The in vitro mutagenic activity was also evaluated by the Salmonella microsome assay (Ames test) for pristimerin and tingenone with and without metabolic activation (S9) in the strains TA98, TA97a, TA100 and TA102, none of which showed mutagenic potential in any strains. Estrogenic and anti-estrogenic activities were also studied by the e-screen assay in MCF-7 cells with negative results. The present data point to the importance of pristimerin and tingenone as representative of an emerging class of potential anticancer chemicals.
publishDate 2011
dc.date.none.fl_str_mv 2011-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000600005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-695X2011000600005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0102-695X2011005000153
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
publisher.none.fl_str_mv Sociedade Brasileira de Farmacognosia
dc.source.none.fl_str_mv Revista Brasileira de Farmacognosia v.21 n.6 2011
reponame:Revista Brasileira de Farmacognosia (Online)
instname:Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron:SBFGNOSIA
instname_str Sociedade Brasileira de Farmacognosia (SBFgnosia)
instacron_str SBFGNOSIA
institution SBFGNOSIA
reponame_str Revista Brasileira de Farmacognosia (Online)
collection Revista Brasileira de Farmacognosia (Online)
repository.name.fl_str_mv Revista Brasileira de Farmacognosia (Online) - Sociedade Brasileira de Farmacognosia (SBFgnosia)
repository.mail.fl_str_mv rbgnosia@ltf.ufpb.br
_version_ 1752122466158772224